Synermore(Suzhou) passed the site inspection for drug production permission

Cultivate benchmarking enterprise clusters and build a world-class high-tech park

Synermore has completed SYN023 Phase I and Phase II clinical trials in the United States and is currently preparing for a global multicenter phase IIb/III trial, as well as a simplified phase I+II clinical trial (bridging trial) in China.

The Clinical Phase I Report for Synermore’s anti-asthma biosimilar drug SYN008 will be submitted to Australia TGA for review

Synermore’s anti-rheumatoid arthritis biosimilar SYN060 approved by the Australian TGA for clinical trial

SYN023, Synermore’s human rabies immunoglobulin antibody drug received IND approval from CFDA for the Clinical Phase I trial study

Synermore’s Cash replenishment of eight trillion and seventy-nine million NT yuan (about 27 million 600 thousand USD) re in place

Synermore’s anti-asthma biosimilar drug SYN008 has been approved by CFDA for human clinical trial phase I

SYN004, an Anti-Colorectal Cancer Antibody Drug Received IND Approval from CFDA

Synermore Attending Bio Taiwan 2016